Bristol-Myers Squibb Co

More Details of Bristol-Myers Squibb Co Company

Company Info

Company codeBMY

Company nameBristol-Myers Squibb Co

IPO dateJul 05, 1929

Founded at1933

CEODr. Christopher S. (Chris) Boerner, Ph.D.

Number of employees34100

Security typeOrdinary Share

Fiscal year-endJul 05

AddressRoute 206 And Province Line Road

CityPRINCETON

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code08543

Phone16092524621

Websitehttps://www.bms.com/in

Company codeBMY

IPO dateJul 05, 1929

Founded at1933

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

5.33K

+65.41%

Ms. Cari Gallman

Executive Vice President, Corporate Affairs, Member of the Leadership Team

5.01K

+137.97%

Mr. Robert Plenge, M.D., Ph.D.

Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team

--

Mr. Peter J. (Pete) Arduini

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

Revenue Breakdown

Currency: USDUpdate time: Wed, Mar 5

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

By RegionUSD

Name

Revenue

Proportion

United States

34.10B

70.61%

International

13.19B

27.32%

other

996.00M

2.06%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

Type

Shareholder

Proportion

Investment Advisor

36.81%

Investment Advisor/Hedge Fund

32.60%

Research Firm

2.76%

Pension Fund

2.50%

Bank and Trust

2.25%

Sovereign Wealth Fund

1.85%

Hedge Fund

1.70%

Holding Company

0.23%

Insurance Company

0.16%

Other

19.10%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

4136

1.64B

81.10%

+16.36M

2024Q4

4261

1.64B

81.14%

+17.04M

2024Q3

4116

1.59B

78.69%

-22.72M

2024Q2

4105

1.58B

78.35%

-83.11M

2024Q1

4118

1.64B

80.97%

+13.32M

2023Q4

4115

1.60B

78.83%

-46.38M

2023Q3

4042

1.62B

77.83%

-55.49M

2023Q2

4082

1.65B

78.77%

-34.93M

2023Q1

4110

1.65B

78.74%

-34.09M

2022Q4

4105

1.65B

77.92%

-72.60M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

189.01M

9.31%

+1.40M

+0.74%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

97.01M

4.78%

-7.45M

-7.13%

Dec 31, 2024

State Street Global Advisors (US)

95.14M

4.68%

+2.24M

+2.42%

Dec 31, 2024

JP Morgan Asset Management

63.09M

3.1%

+12.35M

+24.34%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

60.30M

2.97%

-729.92K

-1.19%

Dec 31, 2024

Capital International Investors

45.86M

2.26%

+3.21M

+7.54%

Dec 31, 2024

Geode Capital Management, L.L.C.

44.39M

2.18%

+1.18M

+2.74%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

35.17M

1.73%

+2.58M

+7.91%

Dec 31, 2024

Columbia Threadneedle Investments (US)

28.49M

1.4%

+12.26M

+75.54%

Dec 31, 2024

Fidelity Management & Research Company LLC

27.55M

1.35%

-9.07M

-24.77%

Dec 31, 2024

Related ETFs

Update time: 13 hours ago

Name

Proportion

First Trust NASDAQ Pharmaceuticals ETF

8.03%

Invesco S&P Ultra Dividend Revenue ETF

6.78%

NYLI Healthy Hearts ETF

4.96%

iShares U.S. Pharmaceuticals ETF

4.8%

Invesco Pharmaceuticals ETF

4.79%

VanEck Morningstar Wide Moat Value ETF

4.58%

VanEck Pharmaceutical ETF

4.37%

Schwab U.S. Dividend Equity ETF

4.3%

Cullen Enhanced Equity Income ETF

3.79%

SPDR S&P Pharmaceuticals ETF

3.67%

First Trust NASDAQ Pharmaceuticals ETF

Proportion8.03%

Invesco S&P Ultra Dividend Revenue ETF

Proportion6.78%

NYLI Healthy Hearts ETF

Proportion4.96%

iShares U.S. Pharmaceuticals ETF

Proportion4.8%

Invesco Pharmaceuticals ETF

Proportion4.79%

VanEck Morningstar Wide Moat Value ETF

Proportion4.58%

VanEck Pharmaceutical ETF

Proportion4.37%

Schwab U.S. Dividend Equity ETF

Proportion4.3%

Cullen Enhanced Equity Income ETF

Proportion3.79%

SPDR S&P Pharmaceuticals ETF

Proportion3.67%

Dividend

A total of 22.71B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Jun 14, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option

Jul 07, 2023

Aug 01, 2023

Jul 06, 2023

Mar 03, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023

Apr 10, 2023

May 01, 2023

Apr 06, 2023

Dec 08, 2022

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023

Jan 06, 2023

Feb 01, 2023

Jan 05, 2023

Sep 14, 2022

BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022

Oct 07, 2022

Nov 01, 2022

Oct 06, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

59.820USD

Bristol-Myers Squibb Co

59.820

Overview

Company